1. Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit. (October 2022) Authors: Mascarella, M.; Olonisakin, T.; Rumde, P.; Vendra, V.; Nance, M.; Kim, S.; Kubik, M.; Sridharan, S.; Ferris, R.; Moon, F.; Clayburgh, D.; Ohr, J.; Joyce, S.; Sen, M.; Herman, J.; Grandis, J.; Zandberg, D.; Duvvuri, U. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗